Naoto T Ueno Selected Research

Triple Negative Breast Neoplasms

4/2024	Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy.
1/2024	Correction: Maternal Embryonic Leucine Zipper Kinase Is Associated with Metastasis in Triple-negative Breast Cancer.
6/2023	Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.
1/2023	Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer.
1/2023	Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer.
1/2022	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
1/2022	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
1/2022	Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape.
10/2021	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.
9/2021	Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naoto T Ueno Research Topics

Disease

141	Neoplasms (Cancer) 05/2023 - 11/2002
135	Breast Neoplasms (Breast Cancer) 04/2024 - 01/2002
57	Inflammatory Breast Neoplasms 04/2024 - 02/2008
50	Neoplasm Metastasis (Metastasis) 01/2024 - 06/2009
35	Triple Negative Breast Neoplasms 04/2024 - 03/2010
18	Pathologic Complete Response 01/2022 - 10/2013
13	Circulating Neoplastic Cells 03/2023 - 07/2009
9	Disease Progression 04/2024 - 06/2004
9	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 07/2005
6	Carcinoma (Carcinomatosis) 09/2020 - 01/2007
5	Carcinogenesis 10/2021 - 03/2010
3	Graft vs Host Disease (Graft-Versus-Host Disease) 06/2008 - 11/2003
3	Renal Cell Carcinoma (Grawitz Tumor) 08/2007 - 11/2003
2	Residual Neoplasm 01/2023 - 01/2022
2	Melanoma (Melanoma, Malignant) 02/2018 - 01/2017
2	Weight Loss (Weight Reduction) 11/2017 - 02/2012

Drug/Important Bio-Agent (IBA)

26	Hormones (Hormone)IBA 01/2022 - 02/2007
21	Proteins (Proteins, Gene)FDA Link 01/2023 - 11/2002
20	Biomarkers (Surrogate Marker)IBA 04/2024 - 12/2009
20	Estrogen ReceptorsIBA 10/2023 - 05/2011
17	ErbB Receptors (EGF Receptor)IBA 06/2021 - 06/2007
16	human ERBB2 proteinIBA 01/2022 - 06/2010
15	Trastuzumab (Herceptin)FDA Link 01/2020 - 06/2004
10	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 04/2004
9	Messenger RNA (mRNA)IBA 01/2023 - 03/2012
9	Progesterone Receptors (Progesterone Receptor)IBA 05/2021 - 01/2011
8	Phosphotransferases (Kinase)IBA 01/2024 - 07/2005
8	Epidermal Growth Factor (EGF)IBA 10/2020 - 06/2004
8	Erlotinib Hydrochloride (CP 358,774)FDA Link 03/2015 - 06/2007
7	Cadherins (E-Cadherin)IBA 01/2023 - 05/2010
7	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 06/2014
7	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 11/2002
7	Lapatinib (GW572016)FDA Link 01/2019 - 07/2008
7	taxaneIBA 01/2018 - 07/2005
6	RNA (Ribonucleic Acid)IBA 05/2023 - 12/2013
6	MicroRNAs (MicroRNA)IBA 01/2018 - 02/2010
5	Phenobarbital (Luminal)FDA Link 01/2022 - 05/2015
5	Estrogens (Estrogen)FDA Link 01/2019 - 01/2011
5	Histone Deacetylase InhibitorsIBA 01/2019 - 11/2012
5	Tyrosine Kinase InhibitorsIBA 07/2014 - 06/2007
4	Immunoconjugates (Immunoconjugate)IBA 10/2023 - 01/2021
4	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 05/2023 - 01/2014
4	LigandsIBA 11/2022 - 11/2010
4	Peptides (Polypeptides)IBA 06/2022 - 04/2014
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 11/2004
4	Transcription Factors (Transcription Factor)IBA 04/2020 - 08/2009
4	AnthracyclinesIBA 01/2018 - 05/2011
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/2017 - 01/2015
4	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2016 - 01/2009
4	Methotrexate (Mexate)FDA LinkGeneric 12/2015 - 11/2003
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2015 - 12/2009
4	fludarabineIBA 06/2008 - 10/2002
3	B7-H1 AntigenIBA 04/2024 - 02/2018
3	entinostat (MS 275)IBA 01/2019 - 07/2014
3	Transforming Growth Factors (Transforming Growth Factor)IBA 12/2017 - 11/2010
3	Cyclin D1IBA 12/2016 - 05/2010
3	Histone Deacetylases (Histone Deacetylase)IBA 05/2016 - 11/2012
3	PhosphoproteinsIBA 01/2015 - 12/2010
3	Tacrolimus (Prograf)FDA LinkGeneric 06/2008 - 11/2003
3	Melphalan (Alkeran)FDA LinkGeneric 02/2008 - 10/2002
2	trastuzumab deruxtecanIBA 10/2023 - 01/2022
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2023 - 10/2021
2	CateninsIBA 01/2023 - 11/2012
2	Celecoxib (Celebrex)FDA Link 01/2023 - 01/2007
2	Immune Checkpoint InhibitorsIBA 12/2022 - 01/2021
2	Everolimus FDA Link 06/2021 - 01/2019
2	AntigensIBA 01/2021 - 02/2007
2	Gemcitabine FDA Link 01/2021 - 01/2011
2	Cisplatin (Platino)FDA LinkGeneric 09/2020 - 01/2020
2	Protein Isoforms (Isoforms)IBA 01/2020 - 07/2014
2	Tamoxifen FDA LinkGeneric 01/2020 - 01/2013
2	CytokinesIBA 08/2019 - 12/2017
2	AgarIBA 06/2019 - 03/2010
2	CholesterolIBA 01/2019 - 04/2015
2	Drug CombinationsIBA 01/2019 - 01/2018
2	TOR Serine-Threonine KinasesIBA 01/2019 - 02/2010
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2019 - 02/2010
2	130-nm albumin-bound paclitaxelIBA 01/2018 - 04/2016
2	KW-2450IBA 01/2018 - 12/2015
2	N- (2,3- dihydroxypropyl)- 1- ((2- fluoro- 4- iodophenyl)amino)isonicotinamideIBA 08/2017 - 01/2015
2	Interleukin-6 (Interleukin 6)IBA 12/2016 - 01/2014
2	Bevacizumab (Avastin)FDA Link 04/2016 - 06/2011
2	Indicators and Reagents (Reagents)IBA 01/2016 - 07/2014
2	AZD 6244IBA 12/2015 - 02/2012
2	PlatinumIBA 12/2015 - 01/2007

Therapy/Procedure

90	Therapeutics 04/2024 - 01/2004
50	Drug Therapy (Chemotherapy) 04/2024 - 05/2003
27	Neoadjuvant Therapy 12/2023 - 11/2004
13	Hematopoietic Stem Cell Transplantation 01/2013 - 05/2003
12	Radiotherapy 10/2022 - 02/2008
5	Mastectomy (Mammectomy) 08/2021 - 01/2014
4	Immunotherapy 04/2024 - 09/2003
4	Transplantation 01/2013 - 06/2004
4	Stem Cell Transplantation 06/2008 - 11/2003
4	Homologous Transplantation 02/2005 - 10/2002
3	Adjuvant Chemotherapy 07/2019 - 12/2015
2	Modified Radical Mastectomy (Mastectomy, Modified) 08/2021 - 11/2020
2	Segmental Mastectomy (Lumpectomy) 10/2017 - 02/2015
2	Precision Medicine 11/2016 - 01/2011
2	Aftercare (After-Treatment) 12/2015 - 02/2008